Current and emerging treatment options for autoimmune hemolytic anemia

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Introduction: Autoimmune hemolytic anemia (AIHA) is a heterogeneous disease mainly due to autoantibody-mediated destruction of erythrocytes but also involves complement activation, dysregulation of cellular and innate immunity, and defective bone marrow compensatory response. Several drugs targeting these mechanisms are under development in addition to standard therapies. Areas covered: The following targeted therapies are illustrated: drugs acting on CD20 (rituximab, alone or in association with bendamustine and fludarabine) and CD52 (alemtuzumab), B cell receptor and proteasome inhibitors (ibrutinib, bortezomib), complement inhibitors (eculizumab, BIVV009, APL-2), and other drugs targeting T lymphocytes (subcutaneous IL-2, belimumab, and mTOR inhibitors), IgG driven extravascular hemolysis (fostamatinib), and bone marrow activity (luspatercept). Expert opinion: Although AIHA is considered benign and often easy to treat, chronic/refractory cases represent a challenge even for experts in the field. Bone marrow biopsy is fundamental to assess one of the main mechanisms contributing to AIHA severity, i.e. inadequate compensation, along with lymphoid infiltrate, the presence of fibrosis or dyserythropoiesis. The latter may give hints for targeted therapies (either B or T cell directed) and for new immunomodulatory drugs. Future studies on the genomic landscape in AIHA will further help in designing the best choice, sequence and/or combination of targeted therapies.

Original languageEnglish
Pages (from-to)857-872
Number of pages16
JournalExpert Review of Clinical Immunology
Volume14
Issue number10
DOIs
Publication statusPublished - Oct 3 2018

Fingerprint

Autoimmune Hemolytic Anemia
Bone Marrow
Complement Inactivating Agents
Drug Delivery Systems
B-Lymphocytes
T-Lymphocytes
Proteasome Inhibitors
Complement Activation
Expert Testimony
Therapeutics
Hemolysis
Innate Immunity
Compensation and Redress
Cellular Immunity
Autoantibodies
Interleukin-2
Fibrosis
Immunoglobulin G
Erythrocytes
Biopsy

Keywords

  • Autoimmune hemolytic anemia
  • cold agglutinin disease
  • complement
  • rituximab
  • targeted therapies

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Current and emerging treatment options for autoimmune hemolytic anemia. / Barcellini, Wilma; Fattizzo, Bruno; Zaninoni, Anna.

In: Expert Review of Clinical Immunology, Vol. 14, No. 10, 03.10.2018, p. 857-872.

Research output: Contribution to journalReview article

@article{ed5290577b694d0a942e7b0d40cd511f,
title = "Current and emerging treatment options for autoimmune hemolytic anemia",
abstract = "Introduction: Autoimmune hemolytic anemia (AIHA) is a heterogeneous disease mainly due to autoantibody-mediated destruction of erythrocytes but also involves complement activation, dysregulation of cellular and innate immunity, and defective bone marrow compensatory response. Several drugs targeting these mechanisms are under development in addition to standard therapies. Areas covered: The following targeted therapies are illustrated: drugs acting on CD20 (rituximab, alone or in association with bendamustine and fludarabine) and CD52 (alemtuzumab), B cell receptor and proteasome inhibitors (ibrutinib, bortezomib), complement inhibitors (eculizumab, BIVV009, APL-2), and other drugs targeting T lymphocytes (subcutaneous IL-2, belimumab, and mTOR inhibitors), IgG driven extravascular hemolysis (fostamatinib), and bone marrow activity (luspatercept). Expert opinion: Although AIHA is considered benign and often easy to treat, chronic/refractory cases represent a challenge even for experts in the field. Bone marrow biopsy is fundamental to assess one of the main mechanisms contributing to AIHA severity, i.e. inadequate compensation, along with lymphoid infiltrate, the presence of fibrosis or dyserythropoiesis. The latter may give hints for targeted therapies (either B or T cell directed) and for new immunomodulatory drugs. Future studies on the genomic landscape in AIHA will further help in designing the best choice, sequence and/or combination of targeted therapies.",
keywords = "Autoimmune hemolytic anemia, cold agglutinin disease, complement, rituximab, targeted therapies",
author = "Wilma Barcellini and Bruno Fattizzo and Anna Zaninoni",
year = "2018",
month = "10",
day = "3",
doi = "10.1080/1744666X.2018.1521722",
language = "English",
volume = "14",
pages = "857--872",
journal = "Expert Review of Clinical Immunology",
issn = "1744-666X",
publisher = "Expert Reviews Ltd.",
number = "10",

}

TY - JOUR

T1 - Current and emerging treatment options for autoimmune hemolytic anemia

AU - Barcellini, Wilma

AU - Fattizzo, Bruno

AU - Zaninoni, Anna

PY - 2018/10/3

Y1 - 2018/10/3

N2 - Introduction: Autoimmune hemolytic anemia (AIHA) is a heterogeneous disease mainly due to autoantibody-mediated destruction of erythrocytes but also involves complement activation, dysregulation of cellular and innate immunity, and defective bone marrow compensatory response. Several drugs targeting these mechanisms are under development in addition to standard therapies. Areas covered: The following targeted therapies are illustrated: drugs acting on CD20 (rituximab, alone or in association with bendamustine and fludarabine) and CD52 (alemtuzumab), B cell receptor and proteasome inhibitors (ibrutinib, bortezomib), complement inhibitors (eculizumab, BIVV009, APL-2), and other drugs targeting T lymphocytes (subcutaneous IL-2, belimumab, and mTOR inhibitors), IgG driven extravascular hemolysis (fostamatinib), and bone marrow activity (luspatercept). Expert opinion: Although AIHA is considered benign and often easy to treat, chronic/refractory cases represent a challenge even for experts in the field. Bone marrow biopsy is fundamental to assess one of the main mechanisms contributing to AIHA severity, i.e. inadequate compensation, along with lymphoid infiltrate, the presence of fibrosis or dyserythropoiesis. The latter may give hints for targeted therapies (either B or T cell directed) and for new immunomodulatory drugs. Future studies on the genomic landscape in AIHA will further help in designing the best choice, sequence and/or combination of targeted therapies.

AB - Introduction: Autoimmune hemolytic anemia (AIHA) is a heterogeneous disease mainly due to autoantibody-mediated destruction of erythrocytes but also involves complement activation, dysregulation of cellular and innate immunity, and defective bone marrow compensatory response. Several drugs targeting these mechanisms are under development in addition to standard therapies. Areas covered: The following targeted therapies are illustrated: drugs acting on CD20 (rituximab, alone or in association with bendamustine and fludarabine) and CD52 (alemtuzumab), B cell receptor and proteasome inhibitors (ibrutinib, bortezomib), complement inhibitors (eculizumab, BIVV009, APL-2), and other drugs targeting T lymphocytes (subcutaneous IL-2, belimumab, and mTOR inhibitors), IgG driven extravascular hemolysis (fostamatinib), and bone marrow activity (luspatercept). Expert opinion: Although AIHA is considered benign and often easy to treat, chronic/refractory cases represent a challenge even for experts in the field. Bone marrow biopsy is fundamental to assess one of the main mechanisms contributing to AIHA severity, i.e. inadequate compensation, along with lymphoid infiltrate, the presence of fibrosis or dyserythropoiesis. The latter may give hints for targeted therapies (either B or T cell directed) and for new immunomodulatory drugs. Future studies on the genomic landscape in AIHA will further help in designing the best choice, sequence and/or combination of targeted therapies.

KW - Autoimmune hemolytic anemia

KW - cold agglutinin disease

KW - complement

KW - rituximab

KW - targeted therapies

UR - http://www.scopus.com/inward/record.url?scp=85054628775&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054628775&partnerID=8YFLogxK

U2 - 10.1080/1744666X.2018.1521722

DO - 10.1080/1744666X.2018.1521722

M3 - Review article

C2 - 30204521

AN - SCOPUS:85054628775

VL - 14

SP - 857

EP - 872

JO - Expert Review of Clinical Immunology

JF - Expert Review of Clinical Immunology

SN - 1744-666X

IS - 10

ER -